Monopar Therapeutics short interest in 2025
In 2025, Monopar Therapeutics's disclosed short interest ran from 0.67% of shares outstanding on 15 Jan 2025 to 15.80% on 31 Dec 2025, a change of +15.13 percentage points. The year's high was 15.80% on 31 Dec 2025 and its low 0.41% on 13 Jun 2025, averaging 3.03% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.70 days on 31 Jul 2025. Full history: Monopar Therapeutics.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 0.67% (15 Jan 2025)
- End of year
- 15.80% (31 Dec 2025)
- Change
- +15.13 pp
- High
- 15.80% (31 Dec 2025)
- Low
- 0.41% (13 Jun 2025)
- Average
- 3.03%
- Highest days to cover
- 6.70 (31 Jul 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 0.67% | 1.00 | |
| 31 Jan 2025 | 0.58% | 1.00 | |
| 14 Feb 2025 | 0.62% | 1.00 | |
| 28 Feb 2025 | 0.97% | 1.11 | |
| 14 Mar 2025 | 0.83% | 1.69 | |
| 31 Mar 2025 | 0.85% | 1.62 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 0.77% | 1.72 | |
| 30 Apr 2025 | 0.72% | 2.81 | |
| 15 May 2025 | 0.62% | 2.00 | 10-Q filed, results (8-K) |
| 30 May 2025 | 0.56% | 2.15 | |
| 13 Jun 2025 | 0.41% | 1.00 | |
| 31 Jul 2025 | 2.20% | 6.70 | |
| 15 Aug 2025 | 2.27% | 5.44 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 2.21% | 3.25 | |
| 15 Sep 2025 | 2.38% | 3.92 | |
| 30 Sep 2025 | 2.40% | 1.76 | |
| 15 Oct 2025 | 2.62% | 1.71 | |
| 31 Oct 2025 | 3.84% | 2.58 | |
| 14 Nov 2025 | 5.55% | 1.99 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 7.59% | 4.04 | |
| 15 Dec 2025 | 12.31% | 4.55 | |
| 31 Dec 2025 | 15.80% | 3.11 |
See also: Monopar Therapeutics's full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.